Your browser doesn't support javascript.
loading
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine, Khaled; Peeva, Elena; Yamaguchi, Yuji; Cox, Lori Ann; Banerjee, Anindita; Han, George; Hamzavi, Iltefat; Ganesan, Anand K; Picardo, Mauro; Thaçi, Diamant; Harris, John E; Bae, Jung Min; Tsukamoto, Katsuhiko; Sinclair, Rodney; Pandya, Amit G; Sloan, Abigail; Yu, Dahong; Gandhi, Kavita; Vincent, Michael S; King, Brett.
Afiliação
  • Ezzedine K; Department of Dermatology, Hôpital Henri Mondor and Université Paris-Est Créteil, EpiDermE - Epidemiology in Dermatology and Evaluation of Therapeutics, Creteil, France. Electronic address: khaled.ezzedine@aphp.fr.
  • Peeva E; Inflammation & Immunology Research Unit, Pfizer, Cambridge, Massachusetts.
  • Yamaguchi Y; Inflammation & Immunology Research Unit, Pfizer, Collegeville, Pennsylvania.
  • Cox LA; Consultant to Pfizer, Basking Ridge, New Jersey.
  • Banerjee A; Clinical Statistics, Pfizer, Cambridge, Massachusetts.
  • Han G; Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
  • Hamzavi I; Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.
  • Ganesan AK; Department of Dermatology, University of California, Irvine, Irvine, California.
  • Picardo M; Cutaneous Physiopathology Laboratory, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
  • Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany.
  • Harris JE; Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts.
  • Bae JM; Department of Dermatology, The Catholic University of Korea, Seoul, South Korea.
  • Tsukamoto K; Department of Dermatology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Sinclair R; Clinical Trials, Sinclair Dermatology, Melbourne, Australia.
  • Pandya AG; Palo Alto Foundation Medical Group, Sunnyvale, California; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Sloan A; Clinical Statistics, Pfizer, Cambridge, Massachusetts.
  • Yu D; Inflammation & Immunology Research Unit, Pfizer, Cambridge, Massachusetts.
  • Gandhi K; Patient & Health Impact, Pfizer, Collegeville, Pennsylvania.
  • Vincent MS; Inflammation & Immunology Research Unit, Pfizer, Cambridge, Massachusetts.
  • King B; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
J Am Acad Dermatol ; 88(2): 395-403, 2023 02.
Article em En | MEDLINE | ID: mdl-36370907
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitiligo Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitiligo Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article